Amarin (AMRN) News
NASDAQ: AMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.03+0.04 (+0.33%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AMRN news summary
We found 3 recent headlines mentioning Amarin (AMRN): 1 in the past week and 3 in the past 30 days, most often from Nasdaq. For price context, AMRN is up 0.33% at $12.03. The most recent story, "argenx Meets Primary Endpoint in Phase II Celiac Disease Study", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Amarin headlines
- argenx Meets Primary Endpoint in Phase II Celiac Disease StudyARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.NasdaqARGX, ALNY, AMRN, ALDX
- Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyMRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.NasdaqMRK, AMRN, ACIU, ARQT
- Teva's Branded Drugs Take Center Stage in Its Growth StrategyTeva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.NasdaqTEVA, SNY, AMRN, ACIU